Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion
ST. LOUIS, June 05, 2023 (GLOBE NEWSWIRE) — Defender Pharmaceuticals, Inc. (the “Company” or “Defender”),…